Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Dosing begins in phase II PEG-rHuPH20 study

Oct. 6, 2011

Celgene and Agios Pharmaceuticals expand cancer metabolism partnership

Oct. 6, 2011

NDA for mechlorethamine gel accepted for review by FDA

Oct. 6, 2011

Johnson & Johnson discloses first-in-human data on pan-histone deacetylase inhibitor

Oct. 6, 2011

Gliknik receives SBIR contract to advance stradobodies

Oct. 5, 2011

EntreMed reports encouraging phase II results on ENMD-2076

Oct. 5, 2011

Novel PP1 inhibitors synthesized

Oct. 5, 2011

New saRNA molecules claimed by University of California scientists

Oct. 5, 2011

Incozen Therapeutics describes new PI3K-delta inhibitor

Oct. 5, 2011

Enrollment complete in pediatric Xerecept trial

Oct. 5, 2011

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...